Literature DB >> 18705236

Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Massimo Franchini1, Pier Mannuccio Mannucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18705236      PMCID： PMC2626866          DOI： 10.2450/2008.0056-07

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  43 in total

Review 1.  Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

2.  Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.

Authors:  Christoph Klaus; Barbara Plaimauer; Jan-Dirk Studt; Friedrich Dorner; Bernhard Lämmle; Pier Mannuccio Mannucci; Friedrich Scheiflinger
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

3.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.

Authors:  Friedrich Scheiflinger; Paul Knöbl; Bettina Trattner; Barbara Plaimauer; Gabriele Mohr; Michael Dockal; Friedrich Dorner; Manfred Rieger
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

4.  von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.

Authors:  Johanna A Kremer Hovinga; Jan-Dirk Studt; Lorenzo Alberio; Bernhard Lämmle
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

Review 5.  Assays of ADAMTS-13 activity.

Authors:  Agnès Veyradier; Jean-Pierre Girma
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

6.  Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.

Authors:  J-D Studt; M Böhm; U Budde; J-P Girma; K Varadi; B Lämmle
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

7.  Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.

Authors:  Paul Coppo; Djaouida Bengoufa; Agnès Veyradier; Martine Wolf; Annette Bussel; Gaël Armel Millot; Sandrine Malot; Farhad Heshmati; Jean-Paul Mira; Emmanuelle Boulanger; Lionel Galicier; Marie-Agnès Durey-Dragon; Véronique Frémeaux-Bacchi; Michel Ramakers; André Pruna; Dominique Bordessoule; Valérie Gouilleux; Marie-Lorraine Scrobohaci; Jean-Paul Vernant; Delphine Moreau; Elie Azoulay; Benoît Schlemmer; Loïc Guillevin; Kaïss Lassoued
Journal:  Medicine (Baltimore)       Date:  2004-07       Impact factor: 1.889

8.  Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.

Authors:  Thomas Raife; Bonnie Atkinson; Robert Montgomery; Sara Vesely; Kenneth Friedman
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

9.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

10.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Richard M Kaufman; Lawrence T Goodnough; J Evan Sadler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113
View more
  10 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

2.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

3.  High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.

Authors:  Ehsan Valavi; Ali Ahmadzadeh; Parisa Amoori; Aidin Daneshgar
Journal:  Indian J Pediatr       Date:  2013-07-28       Impact factor: 1.967

4.  Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Authors:  Ygal Benhamou; Cyrielle Assié; Pierre-Yves Boelle; Marc Buffet; Rana Grillberger; Sandrine Malot; Alain Wynckel; Claire Presne; Gabriel Choukroun; Pascale Poullin; François Provôt; Didier Gruson; Mohamed Hamidou; Dominique Bordessoule; Jacques Pourrat; Jean-Paul Mira; Véronique Le Guern; Claire Pouteil-Noble; Cédric Daubin; Philippe Vanhille; Eric Rondeau; Jean-Bernard Palcoux; Christiane Mousson; Cécile Vigneau; Guy Bonmarchand; Bertrand Guidet; Lionel Galicier; Elie Azoulay; Hanspeter Rottensteiner; Agnès Veyradier; Paul Coppo
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

5.  Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches.

Authors:  Nathan C Edwards; Zachary A Hing; Avital Perry; Adam Blaisdell; David B Kopelman; Robert Fathke; William Plum; Jordan Newell; Courtni E Allen; Geetha S; Aaron Shapiro; Chinyere Okunji; Idit Kosti; Noam Shomron; Vahan Grigoryan; Teresa M Przytycka; Zuben E Sauna; Raheleh Salari; Yael Mandel-Gutfreund; Anton A Komar; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.

Authors:  Vivek A Upadhyay; Benjamin P Geisler; Lova Sun; Lynne Uhl; Richard M Kaufman; Christopher Stowell; Robert S Makar; Pavan K Bendapudi
Journal:  Br J Haematol       Date:  2019-05-26       Impact factor: 8.615

7.  Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population

Authors:  Allison Ching Yee Tso; Christina Lai Lin Sum; Kiat Hoe Ong
Journal:  Singapore Med J       Date:  2020-06-26       Impact factor: 3.331

8.  Thrombotic microangiopathies.

Authors:  Mohamed Radhi; Shannon L Carpenter
Journal:  ISRN Hematol       Date:  2012-07-25

9.  Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors.

Authors:  Suella Martino; Mathieu Jamme; Christophe Deligny; Marc Busson; Pascale Loiseau; Elie Azoulay; Lionel Galicier; Frédéric Pène; François Provôt; Antoine Dossier; Samir Saheb; Agnès Veyradier; Paul Coppo
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

10.  Thrombotic thrombocytopenic purpura possibly triggered by Graves' disease.

Authors:  Saurabh D Chitnis; Tuoyo O Mene-Afejuku; Amandeep Aujla; Ahmed Shady; Gaby S Gil; Eder Hans Cativo; Andrea Popescu-Martinez
Journal:  Oxf Med Case Reports       Date:  2017-10-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.